Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 16

1.

A Src link in schizophrenia.

Hahn CG.

Nat Med. 2011 Apr;17(4):425-7. doi: 10.1038/nm0411-425. No abstract available.

PMID:
21475235
2.

Positive and negative symptoms in schizophrenia: the NMDA receptor hypofunction hypothesis, neuregulin/ErbB4 and synapse regression.

Bennett M.

Aust N Z J Psychiatry. 2009 Aug;43(8):711-21. doi: 10.1080/00048670903001943. Review.

PMID:
19629792
3.

Dysregulated Src upregulation of NMDA receptor activity: a common link in chronic pain and schizophrenia.

Salter MW, Pitcher GM.

FEBS J. 2012 Jan;279(1):2-11. doi: 10.1111/j.1742-4658.2011.08390.x. Review.

4.

Src kinases: a hub for NMDA receptor regulation.

Salter MW, Kalia LV.

Nat Rev Neurosci. 2004 Apr;5(4):317-28. Review. No abstract available.

PMID:
15034556
5.

The N-methyl-D-aspartate receptor and schizophrenia.

Strous RD, Javitt DC.

Isr J Med Sci. 1996 May;32(5):275-81. Review. No abstract available.

PMID:
8641863
6.
7.

The neuregulin-I/ErbB signaling system in development and disease.

Britsch S.

Adv Anat Embryol Cell Biol. 2007;190:1-65. Review.

PMID:
17432114
8.

NMDA receptor regulation by Src kinase signalling in excitatory synaptic transmission and plasticity.

Ali DW, Salter MW.

Curr Opin Neurobiol. 2001 Jun;11(3):336-42. Review.

PMID:
11399432
9.

Reciprocal signalling between NR2 subunits of the NMDA receptor and neuregulin1 and their role in schizophrenia.

Geddes AE, Huang XF, Newell KA.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jun 1;35(4):896-904. doi: 10.1016/j.pnpbp.2011.02.017. Review.

PMID:
21371516
10.

Neuregulin 1 and schizophrenia.

Stefansson H, Steinthorsdottir V, Thorgeirsson TE, Gulcher JR, Stefansson K.

Ann Med. 2004;36(1):62-71. Review.

PMID:
15000348
11.
12.

Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia.

Corfas G, Roy K, Buxbaum JD.

Nat Neurosci. 2004 Jun;7(6):575-80. Review.

PMID:
15162166
13.

Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications.

Gaspar PA, Bustamante ML, Silva H, Aboitiz F.

J Neurochem. 2009 Nov;111(4):891-900. doi: 10.1111/j.1471-4159.2009.06325.x. Review.

14.

Altered growth factor signaling pathways as the basis of aberrant stem cell maturation in schizophrenia.

Kalkman HO.

Pharmacol Ther. 2009 Jan;121(1):115-22. doi: 10.1016/j.pharmthera.2008.11.002. Review.

PMID:
19046988
15.

[Neuropsin signaling as a novel therapeutic target of schizophrenia].

Tawara-Hirata Y.

Nihon Yakurigaku Zasshi. 2014 Mar;143(3):153-5. Review. Japanese. No abstract available.

PMID:
24614639
16.

The discovery of susceptibility genes for mental disorders.

Cloninger CR.

Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13365-7. Review. No abstract available.

Items per page

Supplemental Content

Support Center